An innovative Biotech company About Us
First-in-class disease-modifying products Discover our science
Therapies for neurodegenerative & traumatic disorders Our Pipeline

Our vocation is to develop first-in-class innovative drugs to treat patients with degenerative or traumatic neurological disorders
with high unmet medical needs.

Our ambition is to improve the recovery of the functionality and the quality of life of patients.

Our Discovery

During embryogenesis, a small organ named Subcommisural Organ (SCO) located in the dorsal roof of the brain differentiates and secrets the SCO-spondin, a large multi-domain protein widely distributed in the CNS and with potent activity during neurogenesis.

Learn more

Our Products

Our products are first-in-class multi-target patented peptides with high potential in many CNS disorders, as demonstrated via distinctive and multifunctional mechanism of action on neural cells.

Learn more

Diseases focus

Neurological disorders are diseases of the central and peripheral nervous system. These disorders are of major clinical problems with high unmet medical needs and currently no satisfactory treatment.

Learn more

News

NEUROSCIENCE 2019

Axoltis Pharma announces to attend NEUROSCIENCE 2019, the 50th Annual Meeting of the Society for Neurosciences, on October 19-23th at Chicago, Il, USA. This is a great opportunity to meet with researchers from all over the world and arrange potential collaborative work. Dr Manuel Blanc, Chief Scientific Officer, will be … Read more

PD Therapeutics Conference

Axoltis Pharma announces to attend The Parkinson’s Disease Therapeutics Conference on October 15th at New York City, NY, USA. This … Read more

BIO 2019

Axoltis Pharma announces to attend 2019 BIO International Convention on June 3-6 in Philadelphia, PA – USA, with participation to … Read more